U.S. markets open in 5 hours 41 minutes

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
30.95-0.75 (-2.37%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close31.70
Open30.91
Bid0.00 x 900
Ask0.00 x 800
Day's Range30.33 - 31.41
52 Week Range17.20 - 32.31
Volume415,020
Avg. Volume604,432
Market Cap1.638B
Beta (5Y Monthly)1.20
PE Ratio (TTM)13.11
EPS (TTM)2.36
Earnings DateMay 03, 2021 - May 07, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-4% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Supernus shares soar 13% after FDA approves its new ADHD drug for children
    MarketWatch

    Supernus shares soar 13% after FDA approves its new ADHD drug for children

    U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity.

  • Why Supernus Pharmaceuticals Stock Is Soaring Today
    Motley Fool

    Why Supernus Pharmaceuticals Stock Is Soaring Today

    On Friday afternoon, Supernus Pharmaceuticals (NASDAQ: SUPN) announced that the U.S. Food and Drug Administration (FDA) had approved Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients between the ages of 6 to 17. As a result of this regulatory update, shares of the biopharmaceutical company are rising sharply on Monday and were up by 10.2% as of 1:49 p.m. EDT after jumping by as much as 11.4% earlier in the day. It hasn't been an easy road for Supernus Pharmaceuticals' attempt to earn approval for Qelbree: The company conducted four phase 3 clinical trials with over 1,000 ADHD patients to demonstrate the safety and efficacy of this medicine.

  • Supernus (SUPN) Receives FDA Approval for ADHD Treatment
    Zacks

    Supernus (SUPN) Receives FDA Approval for ADHD Treatment

    Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.